Cargando…
Contribution of Hypothermia and CB(1) Receptor Activation to Protective Effects of TAK-937, a Cannabinoid Receptor Agonist, in Rat Transient MCAO Model
BACKGROUND: Cannabinoid (CB) receptor agonists are expected to alleviate ischemic brain damage by modulating neurotransmission and neuroinflammatory responses via CB(1) and CB(2) receptors, respectively. In a previous study, TAK-937, a novel potent and selective CB(1) and CB(2) receptor agonist, was...
Autores principales: | Suzuki, Noriko, Suzuki, Motohisa, Hamajo, Kazuhiro, Murakami, Koji, Tsukamoto, Tetsuya, Shimojo, Masato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3397930/ https://www.ncbi.nlm.nih.gov/pubmed/22815855 http://dx.doi.org/10.1371/journal.pone.0040889 |
Ejemplares similares
-
Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB(2)
receptor
por: Patel, Monica, et al.
Publicado: (2023) -
Preclinical characterization of AMPA receptor potentiator TAK‐137 as a therapeutic drug for schizophrenia
por: Tanaka, Maiko, et al.
Publicado: (2019) -
Exploring determinants of agonist efficacy at the CB1 cannabinoid receptor: Analogues of the synthetic cannabinoid receptor agonist EG‐018
por: Finlay, David B., et al.
Publicado: (2022) -
Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity
por: Franks, Lirit N., et al.
Publicado: (2016) -
Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence
por: Ibsen, Mikkel Søes, et al.
Publicado: (2019)